NEW YORK – The U.S. government’s first look at the real-world use of COVID-19 vaccines found their effectiveness was nearly as robust as it was in controlled studies.
The two vaccines available since December — Pfizer and Moderna — were highly effective at 90% after two doses, the Centers for Disease Control and Prevention reported Monday. In testing, the vaccines were about 95% effective in preventing COVID-19.
“This is very reassuring news,” said the CDC’s Mark Thompson, the study’s lead author. “We have a vaccine that’s working very well.”
The study is the government’s first assessment of how the shots have been working beyond the drugmakers' initial experiments. Results can sometimes change when vaccines are used in larger, more diverse populations outside studies.
With nearly 4,000 participants from six states, the study focused on health care workers, first responders and other front-line workers who had first priority for the shots because they are at higher risk. They were given nasal swab test kits to use every week to check for signs of a coronavirus infection.
“The evidence base for (currently available) COVID-19 vaccines is already strong, and continues to mount ever higher with studies like this one,” said David Holtgrave, dean of the University at Albany's School of Public Health, in an email.
The study included roughly 2,500 volunteers who had completed two vaccine doses, about 500 who got one dose and about 1,000 who did not get vaccinated between mid-December and mid-March.
The researchers counted 205 infections, with 161 of them in the unvaccinated group. Of the remaining 44, the CDC said 33 of them were in people apparently infected within two weeks of a shot. Experts say it takes two weeks before a dose takes full effect.